Dr. Paula van Noort
Phone: +31 302539549
Fax: +31 302539176
Thijs De Gunst, M.Sc.
InteRNA is a Dutch drug discovery and development company engaged in the development of novel breakthrough therapies in chronic disorders, e.g. cancer and CNS diseases, based on the unique functions of its proprietary miRNAs. InteRNA's drug development programs aim at developing miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes that are known to play a role in the initiation and progression of chronic disorders. At present, miRNA findings are captured in seven patent families all claiming miRNAs key in the diagnosis or treatment of chronic disorders.
This EpiMiRNA project benefits from InteRNA’s platform for discovery and validation of miRNA-based drug candidates which is based on its proprietary lentiviral-based miRNA expression library (which is the largest currently available) that allows for high throughput functional screening in cell based assays. With InteRNA's proprietary miRNA expression database (generated through deep sequencing) and additional technologies (like RNAseq, PAR-CLIP, bioinformatics, in vivo models) in place to identify the downstream regulated proteins for each miRNA drug candidate, InteRNA has the platforms in place to move novel miRNA drug candidates with their biomarkers quickly towards the clinic.
InteRNA has four years of experience in project management as consortium leader in a Dutch-based consortium with academic partners funded by Top Institute Pharma, was and is still partner in several national or international public sponsored research projects, e.g. the Sirocco FP6 and MiRacle FP7 projects, and has multiple international academic and corporate R&D partners.